Russia's Rusnano supports HSCI/Pharmsynthez's $100 million new drugs development project
This article was originally published in Scrip
Executive Summary
A project proposed by Moscow-based company HSCI (Human Stem Cells Institute), in which St Petersburg-based Pharmsynthez will also take part, will receive financial support from Russia's state corporation of nanotechnologies, Rusnano. Pharmsynthez estimated that the project would cost Rb3 billion ($100 million).